Company Filing History:
2 out of 11 
1 out of 5 Years Active: 2012-2013
Title: Innovations of César Sánchez Reillo
Introduction
César Sánchez Reillo is a notable inventor based in Oviedo, Spain. He has made significant contributions to the field of pharmaceuticals through his innovative work on glycosylated indolocarbazoles and methods for their production. His inventions are particularly relevant for the treatment of various diseases, including tumors and neurological disorders.
Latest Patents
César Sánchez Reillo holds two patents. The first patent is titled "Glycosylated indolocarbazoles, method for obtaining same and uses thereof." This invention focuses on derivatives of rebeccamycin and staurosporine obtained through the fermentation of recombinant bacterial strains. It also details the methods for obtaining these recombinant strains and the production of the derivatives, which have applications in human health. The second patent is "Method of obtaining indolocarbazoles using biosynthetic rebeccamycin genes." This invention utilizes rebeccamycin biosynthetic genes for the production of indolocarbazoles in related microorganisms. It includes the isolation of a DNA fragment containing the rebeccamycin biosynthesis gene cluster and the expression of these genes, making it suitable for pharmaceutical applications.
Career Highlights
César Sánchez Reillo has worked with esteemed institutions such as the University of Oviedo and Entrechem, S.L. His research and innovations have positioned him as a key figure in the development of new pharmaceutical methods and compounds.
Collaborations
César has collaborated with notable individuals in his field, including Aaroa Pérez Salas and Alfredo Fernández Braña. Their joint efforts have contributed to the advancement of his research and the successful development of his patents.
Conclusion
César Sánchez Reillo's work exemplifies the intersection of innovation and health, showcasing the potential of his inventions to impact the pharmaceutical industry positively. His contributions continue to pave the way for advancements in drug development and treatment methodologies.